Equitec Proprietary Markets, LLC Gracell Biotechnologies Inc. Call Options Transaction History

Equitec Proprietary Markets, LLC

  • $92.9 Million
  • Q3 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Jan 29, 2024
BUY
$2.43 - $10.04 $2,673 - $11,043
1,100 New
1,100 $11,000

Others Institutions Holding GRCL

# of Institutions
2
Shares Held
75.1K
Call Options Held
0
Put Options Held
0
View Full List

About Gracell Biotechnologies Inc.

GRCL Quotes by TradingView
  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Equitec Proprietary Markets, LLC Portfolio

Follow Equitec Proprietary Markets, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Equitec Proprietary Markets, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Equitec Proprietary Markets, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email